Analyst Price Target is GBX 0
This price target is based on 0 analysts offering 12 month price targets for InnovaDerma in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a NaN upside from the last price of GBX 0.
Current Consensus is
N/A
The current consensus among 0 investment analysts is to n/a stock in InnovaDerma. This N/A consensus rating has held steady for over two years.
InnovaDerma PLC, through its subsidiaries, engages in the research, manufacture, and marketing of clinically proven products in life sciences, beauty, and personal care products in the United Kingdom, the United States, Australasia, and the Asia Pacific region. The company offers a range of men's skincare products, including hand and body washes, hand creams, face washes, and face moisturizers under the Charles + Lee brand name; and hair removal wax and jelly, and shave and shower sorbet under the Nuthing brand. It also provides tanning mousses, tanning gels, tanning oils, primers, moisturizers, and applicators under the Skinny Tan brand name; Prolong, a Class II medical device for the treatment of premature ejaculation; haircare products comprising shampoos, conditioners, and spray treatment for men and women to aid hair regrowth and hair thickening under the Roots brand name; and hair growth products under the GrowLase brand. The company sells its products through online and DTC channels. InnovaDerma PLC was incorporated in 2014 and is headquartered in London, the United Kingdom.
Read More
